EA200500894A1 - Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторы - Google Patents

Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторы

Info

Publication number
EA200500894A1
EA200500894A1 EA200500894A EA200500894A EA200500894A1 EA 200500894 A1 EA200500894 A1 EA 200500894A1 EA 200500894 A EA200500894 A EA 200500894A EA 200500894 A EA200500894 A EA 200500894A EA 200500894 A1 EA200500894 A1 EA 200500894A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
nniot
combination
cytochrome
application
Prior art date
Application number
EA200500894A
Other languages
English (en)
Inventor
Майкл Грэм Кордингли
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA200500894A1 publication Critical patent/EA200500894A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

В заявке описан усовершенствованный способ применения ННИОТ для лечения вызываемой ВИЧ-1 инфекции, заключающийся в том, что человеку, нуждающемуся в лечении вызываемой ВИЧ-1 инфекции, вводят терапевтически эффективное количество ННИОТ или его фармацевтически приемлемой соли и количество ингибитора цитохромов P450, которое является достаточным для повышения, усиления или расширения концентрации ННИОТ в плазме.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500894A 2002-12-16 2003-12-15 Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторы EA200500894A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43369002P 2002-12-16 2002-12-16
PCT/EP2003/014224 WO2004054586A1 (en) 2002-12-16 2003-12-15 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Publications (1)

Publication Number Publication Date
EA200500894A1 true EA200500894A1 (ru) 2006-02-24

Family

ID=32595224

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500894A EA200500894A1 (ru) 2002-12-16 2003-12-15 Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторы

Country Status (20)

Country Link
US (2) US20040152625A1 (ru)
EP (1) EP1575595A1 (ru)
JP (1) JP2006511538A (ru)
KR (1) KR20050085681A (ru)
CN (1) CN1726041A (ru)
AU (1) AU2003296647A1 (ru)
BR (1) BR0317095A (ru)
CA (1) CA2510143A1 (ru)
EA (1) EA200500894A1 (ru)
EC (1) ECSP055854A (ru)
HR (1) HRP20050557A2 (ru)
IL (1) IL169099A0 (ru)
MX (1) MXPA05005773A (ru)
NO (1) NO20053455L (ru)
NZ (1) NZ541187A (ru)
PL (1) PL376900A1 (ru)
RS (1) RS20050461A (ru)
UA (1) UA81003C2 (ru)
WO (1) WO2004054586A1 (ru)
ZA (1) ZA200502947B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ES2539527T3 (es) * 2005-04-27 2015-07-01 Taimed Biologics, Inc. Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
AU2006319716B2 (en) 2005-11-30 2012-02-02 Taimed Biologics, Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
CN1907138B (zh) * 2006-08-11 2011-01-12 华南师范大学 一种沙田柚子汁提取物及其提取方法和应用
JP5401652B2 (ja) 2006-09-21 2014-01-29 タイメッド バイオロジクス インコーポレイテッド プロテアーゼ阻害剤
NZ595280A (en) 2009-02-27 2013-11-29 Enanta Pharm Inc Hepatitis c virus inhibitors
JP5523552B2 (ja) 2009-04-25 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 薬物動態を改善する方法
EP2429568B1 (en) 2009-05-13 2016-08-17 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2285577A1 (en) * 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
JP2002528502A (ja) * 1998-11-04 2002-09-03 ファルマシア・アンド・アップジョン・カンパニー チプラナビルの薬物動態を改善する方法
US6391919B1 (en) * 2000-01-12 2002-05-21 Bristol-Myers Squibb Pharma Company Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
TWI270547B (en) * 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
WO2004085437A1 (en) * 2002-09-19 2004-10-07 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
US20040152625A1 (en) 2004-08-05
HRP20050557A2 (en) 2006-05-31
ECSP055854A (es) 2006-01-16
RS20050461A (en) 2007-08-03
CA2510143A1 (en) 2004-07-01
ZA200502947B (en) 2008-01-30
MXPA05005773A (es) 2005-08-16
NO20053455L (no) 2005-08-10
IL169099A0 (en) 2007-07-04
BR0317095A (pt) 2005-10-25
AU2003296647A1 (en) 2004-07-09
US20080096832A1 (en) 2008-04-24
UA81003C2 (en) 2007-11-26
EP1575595A1 (en) 2005-09-21
NZ541187A (en) 2007-12-21
KR20050085681A (ko) 2005-08-29
PL376900A1 (pl) 2006-01-09
WO2004054586A1 (en) 2004-07-01
JP2006511538A (ja) 2006-04-06
CN1726041A (zh) 2006-01-25

Similar Documents

Publication Publication Date Title
EA200500894A1 (ru) Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторы
UY35542A (es) Métodos y composiciones para tratar el virus de la hepatitis c
NO20062428L (no) Kombinasjoner for HCV-behandling
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
ATE350374T1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
EA200500859A1 (ru) Хинолинилпирролопиразолы
EA200200324A1 (ru) Способы применения селективных ингибиторов обратного захвата серотонина быстрого запуска для лечения половой дисфункции
EA201100506A1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
WO2004010937A3 (en) Method of treating cancer
EA200401240A1 (ru) Применение ингибиторов il-18 для лечения и/или профилактики заболеваний периферических сосудов
DK1581235T3 (da) Anvendelse af spongosin (2-methoxyadenosin) til behandling af smerte i særdeleshed hyperalgesi
DK1949893T3 (da) Quinazolinderivater, der kan anvendes til behandling af perifer arteriel sygdom og som phosphodiesteraseinhibitorer
EA200200502A1 (ru) Способ введения ингибитора фосфодиэстеразы 4
EA200300844A1 (ru) Использование ингибиторов il-18 для лечения и/или профилактики заболевания сердца
HUP0204551A2 (hu) Eljárás a pikkelysömör kezelésére
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
EA200000513A1 (ru) Комбинированная терапия для лечения спид
EA200400817A1 (ru) Идрапаринукс для лечения и вторичной профилактики случаев венозной тромбоэмболии у пациентов с тромбозом глубоких вен